"People tend to think that if direct-to-consumer advertising wasn't effective, pharma wouldn't be doing it," says Harvard Medical School professor Stephen Soumerai, principal investigator on the study. "But as it turns out, decisions to market directly to consumers is based on scant data."
This study was based at the Department of Ambulatory Care and Prevention of Harvard Medical School and Harvard Pilgrim Health Care and appears September 2 online in the British Medical Journal. It is the first-ever controlled study of direct-to-consumer advertising (DTCA) of pharmaceuticals.
Currently, the United States and New Zealand are the only countries that allow drug companies to advertise directly to patients. When the U.S. Food and Drug Administration eased advertising restrictions on the pharmaceutical industry in 1997, consumer advertising jumped 330 percent over the next 10 years. As of 2005, pharma was spending about $5 billion annually on such campaigns. Some data implied that such ads increased prescriptions, but these studies simply correlated ads with sales, begging the question, are drugs that sell more simply advertised more?
But examining the effects of advertising on sales via a controlled study is problematic. Given the overwhelming amount of advertising in the U.S., how do you find two groups that are very similar, yet one is exposed to pharmaceutical advertising and the other isn't?
The answer: Canada.
DTCA is illegal in Canada. Not surprisingly, however, national borders are leaky and American media—television and magazines and radio, replete with pharma ads—regularly crosses into Canada. As a result, Canadians, like Americans, are swamped with these ads, with one key exception.
All American advertisements are in English. Yet Canada has a significant French-speaking population. In the Canadian province of Quebec, approximately 80 percent of its 7.5 million population speak French as their first language, and tend to get most of their news from French-language media. As a result, residents of Quebec, on the whole, are far less exposed to DTCA than other Canadians.
Quebec, then, functioned as a control group for the study. The researchers compared prescription rates for advertised drugs in English-speaking Canadian provinces with rates in Quebec, where residents were purportedly less exposed to those same ads.
"It's not an absolutely perfect control group," says Michael Law, first author on the paper. "There's obviously a small percentage of Quebec residents who are exposed to English language media. But as control groups go for this sort of observational study, it's about as good as you get."
Law and Soumerai chose to look at three specific drugs: Enbrel (rheumatoid arthritis), Nasonex (nasal allergies), and Zelnorm (irritable bowel sydrome). All three drugs were on the market for at least one year before the DTCA campaign began, and none were advertised in Canada through "softer" consumer ads, that is, ads that may mention the drug by name without identifying the relevant conditions.
The basic question was simple: did use of these drugs increase faster in English-speaking regions after American DTCA campaigns began?
Using information from IMS Health Canada, a health information company that receives data from a panel of about 2,700 Canadian pharmacies, the researchers analyzed prescription statistics for each of these three drugs for a five-year period.
They found that for two of the drugs, Enbrel and Nasonex, DTCA had no effect whatsoever. Prescription patterns in English-speaking Canada and in Quebec remained identical both before and after DTCA campaigns began.
Sales for Zelnorm, however, did spike noticeably in English-speaking Canada as soon as the ad campaign began. While prescriptions for this drug increased by over 40 percent, this jump was relatively short-lived, and after a few years, prescription rates in both groups resumed identical patterns. A similar analysis of U.S. Medicaid prescriptions found a slightly higher, but similarly brief, jump in sales.
The researchers hypothesize that DTCA may not be as effective as other types of consumer advertising due to the unique complexity of the marketing/sales trajectory.
With a typical consumer product, an individual sees an ad and then can choose to simply go out and buy the item. "But pharmaceuticals aren't typical consumer products," says Soumerai. "A person needs to see an ad, get motivated by that ad, contact their doctor for an appointment, show up at the appointment, communicate both the condition and the drug to the doctor, convince the doctor that this drug is preferable to other alternatives, then actually go out and fill the prescription. This is a chain of events that can break at any point."
This hypothesis may in fact explain the disparate effects of DTCA on these three drugs. For Enbrel and Nasonex, there are a number of over-the-counter and prescription alternatives that doctors would likely recommend as first-line treatments.
Zelnorm, however, was the only drug on the market in both the United States and Canada for constipation-predominant irritable bowel syndrome. The researchers suggest that Zelnorm would have sold very well without the consumer advertising.
In March of 2007, Zelnorm was pulled from the market due to FDA concerns that it may increase risk for heart attack and stroke.
One hundred years of marketing experience and recent studies indicate that face-to-face promotion of drugs to doctors by pharmaceutical representatives is far more effective than DTCA.
Drone vs. truck deliveries: Which create less carbon pollution?
31.05.2017 | University of Washington
New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology